Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis

• Status: Completed
• Trial end date: 2017-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with treatment-resistant pruritus diagnosed with atopic dermatitis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Vanda Pharmaceuticals

Criteria

Inclusion Criteria:

• Male and non-pregnant, non-lactating female subjects aged 18 - 65 years (inclusive);

• Diagnosed with atopic dermatitis

• Suffering from chronic pruritus with pruritus being actively present

Exclusion Criteria:

• Chronic pruritus due to condition other than atopic dermatitis (AD)

• Participation in a previous tradipitant (LY686017 or VLY-686) trial;

• Anyone affiliated with the site or sponsor and/or anyone who may consent under duress;

• Any other sound medical reason as determined by the Investigator including any condition which may lead to an unfavorable risk-benefit of study participation, may interfere with study compliance or may confound study results.